AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

We currently know that COPD, and specifically emphysema, is not just a lung disease found alongside lung cancer; it increases ...

GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...

AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...

Mount Sinai researchers showed that deep learning applied to standard ECGs accurately detected chronic obstructive pulmonary ...

Quitting smoking and avoiding vaping may be crucial steps in managing COPD, as these habits expose your lungs to irritants that cause further damage. Quitting may slow the disease’s progression and ...

GlaxoSmithKline’s (GSK) Nucala (mepolizumab) has been approved by the MHRA to treat adults with uncontrolled chronic ...

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that include chronic bronchitis and emphysema. It’s a chronic condition that makes breathing difficult, and can lead to ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...

Cold waves with dipping temperatures, along with severe air pollution, are driving a sharp rise in heart and respiratory ...